Incyte (INCY) stock forecast for 2023
Last update: 08-15-2022, 6:06
Sector: HealthcareThe share price of Incyte Corp. (INCY) now
What analysts predict:: $87.8
52-week high/low: $84.86 / $61.91
50/200 Day Moving Average: $76.01 / $73.44
This figure corresponds to the average price over the previous 50/200 days. For Incyte stocks, the 50-day moving average is the resistance level today.
For Incyte stocks, the 200-day moving average is the resistance level today.
Are you interested in Incyte stocks and want to buy them, or are they already in your portfolio? If yes, then on this page you will find useful information about the dynamics of the Incyte stock price in 2023. How much will one Incyte share be worth in 2023?
Is it worth taking profit / loss on Incyte stock now or waiting? What are analysts' forecasts for Incyte stock?
We forecast Incyte stock performance using neural networks based on historical data on Incyte stocks. Also, when forecasting, technical analysis tools are used, world geopolitical and news factors are taken into account.
The Incyte stock prediction results are shown below and presented as a graph, table and text information.
Incyte stock forecasts are adjusted once a day based on the closing price of the previous trading day.
The minimum target price for Incyte analysts is $87.8.
Today 200 Day Moving Average is the resistance level (73.44 $).
50 Day Moving Average is the resistance level (76.01 $).
Historical and forecast chart of Incyte stock
The chart below shows the historical price of Incyte stock and a prediction chart for the next year. For convenience, prices are divided by color. Forecast prices include: Optimistic Forecast, Pessimistic Forecast, and Weighted Average Best Forecast. Detailed values for the Incyte stock price can be found in the table below.
Incyte (INCY) Forecast for 2023
| Month | Target | Pes. | Opt. | Vol., % |
|---|---|---|---|---|
| Jan | 80.46 | 78.87 | 83.94 | 6.04 % |
| Feb | 78.43 | 75.12 | 83.09 | 9.60 % |
| Mar | 83.66 | 81.10 | 89.53 | 9.42 % |
| Apr | 87.42 | 85.06 | 89.15 | 4.59 % |
| May | 91.12 | 84.89 | 96.61 | 12.14 % |
| Jun | 87.27 | 84.28 | 91.74 | 8.13 % |
| Jul | 86.40 | 83.68 | 91.46 | 8.50 % |
| Aug | 87.88 | 81.55 | 91.60 | 10.97 % |
| Sep | 87.33 | 83.63 | 89.45 | 6.50 % |
| Oct | 89.21 | 84.23 | 94.35 | 10.72 % |
| Nov | 87.53 | 83.35 | 90.44 | 7.84 % |
| Dec | 84.30 | 78.23 | 87.10 | 10.19 % |
Incyte information and performance
Incyte Corp is an American pharmaceutical company. The company was founded in Palo Alto, California in 1991 and became famous in 1993. Incyte has one drug, Jakafi, which has been approved by the US Food and Drug Administration (FDA) and has been prescribed to patients in the United States.
Incyte Address
1801 AUGUSTINE CUT-OFF, WILMINGTON, DE, US
Market Capitalization: 16 457 670 000 $
Market capitalization is the total market value of all issued shares of a company. It is calculated by the formula multiplying the number of shares in the company outstanding by the market price of one share.
EBITDA: 797 299 000 $
EBITDA is earnings before interest, income tax and depreciation of assets.
PE Ratio: 17.37
P/E ratio (price to earnings) - shows the ratio between the price of a share and the company's profit
PEG Ratio: 0.695
Price/earnings to growth
DPS: N/A
Dividend Per Share is a financial indicator equal to the ratio of the company's net profit available for distribution to the annual average of ordinary shares.
DY: N/A
Dividend yield is a ratio that shows how much a company pays in dividends each year at the stock price.
EPS: 4.26
EPS shows how much of the net profit is accounted for by the common share.
Quarterly Earnings Growth YOY: 0.075
Quarterly Revenue Growth YOY: 0.291
Trailing PE: 17.37
Trailing P/E depends on what has already been done. It uses the current share price and divides it by the total earnings per share for the last 12 months.
Forward PE: 22.32
Forward P/E uses projections of future earnings instead of final numbers.
EV To Revenue: 4.159
Enterprise Value (EV) /Revenue
EV To EBITDA: 19.89
The EV / EBITDA ratio shows the ratio of the cost (EV) to its profit before tax, interest and amortization (EBITDA).
Shares Outstanding: 222431000
Number of issued ordinary shares
Shares Float: N/A
Number of freely tradable shares
Shares Short Prior Month: N/A
Shares Short Prior Month - the number of shares in short positions in the last month.
Short Ratio: N/A
Percent Insiders: N/A
Percent Institutions: N/A
Incyte price target for 2021 by month
Target values for the price of one Incyte share for Jan 2023.
Pessimistic target level: 78.87
Optimistic target level: 83.94
Target values for the price of one Incyte share for Feb 2023.
Pessimistic target level: 75.12
Optimistic target level: 83.09
Target values for the price of one Incyte share for Mar 2023.
Pessimistic target level: 81.10
Optimistic target level: 89.53
Target values for the price of one Incyte share for Apr 2023.
Pessimistic target level: 85.06
Optimistic target level: 89.15
Target values for the price of one Incyte share for May 2023.
Pessimistic target level: 84.89
Optimistic target level: 96.61
Target values for the price of one Incyte share for Jun 2023.
Pessimistic target level: 84.28
Optimistic target level: 91.74
Target values for the price of one Incyte share for Jul 2023.
Pessimistic target level: 83.68
Optimistic target level: 91.46
Target values for the price of one Incyte share for Aug 2023.
Pessimistic target level: 81.55
Optimistic target level: 91.60
Target values for the price of one Incyte share for Sep 2023.
Pessimistic target level: 83.63
Optimistic target level: 89.45
Target values for the price of one Incyte share for Oct 2023.
Pessimistic target level: 84.23
Optimistic target level: 94.35
Target values for the price of one Incyte share for Nov 2023.
Pessimistic target level: 83.35
Optimistic target level: 90.44
Target values for the price of one Incyte share for Dec 2023.
Pessimistic target level: 78.23
Optimistic target level: 87.10
